Stryker (SYK) Expected to Release Quarterly Earnings on Thursday

Key Points

• Stryker is expected to report Q3 2026 earnings after Thursday’s market close, with analysts forecasting $3.55 in EPS and $6.62 billion in revenue. The company’s full-year EPS guidance is $14.950–$15.100.
• In the prior quarter, Stryker exceeded expectations with $3.69 EPS and $6.59 billion in revenue, while sales rose 9.4% year over year. Analysts currently maintain a “Moderate Buy” consensus rating with an average price target of $369.
• Stryker shares opened at $297.30 and are down 2.3%, while the company declared a quarterly dividend of $0.88 per share, representing a 1.2% annualized yield.

Stryker (NYSE:SYK - Get Free Report) is projected to post its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect Stryker to post earnings of $3.55 per share and revenue of $6.62 billion for the quarter. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The business's revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the firm earned $3.13 earnings per share. On average, analysts expect Stryker to post $14.93 EPS for the current fiscal year and $16.60 EPS for the next fiscal year.

Stryker Trading Down 2.3%

Shares of NYSE SYK opened at $297.30 on Thursday. The stock has a market cap of $114.03 billion, a price-to-earnings ratio of 30.81, a PEG ratio of 1.96 and a beta of 0.78. The business has a 50 day simple moving average of $296.53 and a 200 day simple moving average of $312.13. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker has a 52 week low of $267.00 and a 52 week high of $392.55.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker's dividend payout ratio is currently 36.48%.

Insiders Place Their Bets

In other news, insider Debra King sold 826 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dylan Crotty sold 441 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider owned 6,102 shares of the company's stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 351,267 shares of company stock worth $118,197,701 over the last three months. 4.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SYK shares. Citizens Jmp lowered their price objective on Stryker from $440.00 to $400.00 and set a "market outperform" rating on the stock in a report on Monday, August 3rd. Wells Fargo & Company cut their target price on shares of Stryker from $418.00 to $348.00 and set an "overweight" rating for the company in a research report on Wednesday, September 9th. Evercore set a $350.00 price objective on Stryker in a research note on Monday, July 6th. Royal Bank Of Canada dropped their price target on Stryker from $435.00 to $420.00 and set an "outperform" rating on the stock in a research report on Friday, July 31st. Finally, Truist Financial lowered their price objective on shares of Stryker from $340.00 to $310.00 and set a "hold" rating on the stock in a research note on Tuesday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $369.00.

About Stryker

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.